Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic SteatohepatitisSummary

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic SteatohepatitisSummary

Background & Aims: Pharmacologic agents targeting bile acid signaling show promise for treating nonalcoholic steatohepatitis (NASH). However, clinical findings suggest that new treatment strategies with enhanced therapeutic efficacy and minimized undesired effects are needed. This preclinica...

Full description

Bibliographic Details
Main Authors: David J. Matye, Huaiwen Wang, Wenyi Luo, Rachel R. Sharp, Cheng Chen, Lijie Gu, Kenneth L. Jones, Wen-Xing Ding, Jacob E. Friedman, Tiangang Li
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Cellular and Molecular Gastroenterology and Hepatology
Subjects:
Bile Acids
Fatty Liver
CYP7A1
NASH
Liver Fibrosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2352345X21000849

Internet

http://www.sciencedirect.com/science/article/pii/S2352345X21000849

Similar Items